[1]CHEN R,SMITH-COHN M,COHEN AL,et al.Glioma subclassifications and their clinical significance[J].Neurotherapeutics,2017,14(2):284-297.
[2]LE RHUN E,PREUSSER M,ROTH P,et al.Molecular targeted therapy of glioblastoma[J].Cancer Treat Rev,2019,80:101896.
[3]OBERHEIM BUSH NA,HERVEY-JUMPER SL,BERGER MS.Management of glioblastoma,present and future[J].World Neurosurg,2019,131:328-338.
[4]JACKSON CM,CHOI J,LIM M.Mechanisms of immunotherapy resistance:lessons from glioblastoma[J].Nat Immunol,2019,20(9):1100-1109.
[5]BOCCALETTO P,MACHNICKA MA,PURTA E,et al.MODOMICS:a database of RNA modification pathways.2017 update[J].Nucleic Acids Res,2018,46(D1):D303-D307.
[6]YUE Y,LIU J,HE C.RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation[J].Genes Dev,2015,29(13):1343-1355.
[7]DESROSIERS R,FRIDERICI K,ROTTMAN F.Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells[J].Proc Natl Acad Sci USA,1974,71(10):3971-3975.
[8]JONKHOUT N,TRAN J,SMITH MA,et al.The RNA modification landscape in human disease[J].Rna,2017,23(12):1754-1769.
[9]FRYE M,HARADA BT,BEHM M,et al.RNA modifications modulate gene expression during development[J].Science,2018,361(6409):1346-1349.
[10]KARTHIYA R,KHANDELIA P.m6A RNA methylation:Ramifications for gene expression and human health[J].Mol Biotechnol,2020,62(10):467-484.
[11]LIU ZX,LI LM,SUN HL,et al.Link between m6A modification and cancers[J].Front Bioeng Biotechnol,2018,6:89.
[12]SUN T,WU R,MING L.The role of m6A RNA methylation in cancer[J].Biomed Pharmacother,2019,112:108613.
[13]YANG Y,HSU PJ,CHEN YS,et al.Dynamic transcriptomic m(6)A decoration:writers,erasers,readers and functions in RNA metabolism[J].Cell Res,2018,28(6):616-624.
[14]ZHANG Y,GENG X,LI Q,et al.m6A modification in RNA:biogenesis,functions and roles in gliomas[J].J Exp Clin Cancer Res,2020,39(1):192.
[15]QU S,CHEN Z,LIU B,et al.N6-methyladenine-related genes affect biological behavior and the prognosis of glioma[J].Cancer Med,2021,10(1):98-108.
[16]ZHENG W,DONG X,ZHAO Y,et al.Multiple functions and mechanisms underlying the role of METTL3 in human cancers[J].Front Oncol,2019,9:1403.
[17]ZENG C,HUANG W,LI Y,et al.Roles of METTL3 in cancer:mechanisms and therapeutic targeting[J].J Hematol Oncol,2020,13(1):117.
[18]CHOE J,LIN S,ZHANG W,et al.mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis[J].Nature,2018,561(7724):556-560.
[19]JIN D,GUO J,WU Y,et al.m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis[J].J Hematol Oncol,2019,12(1):135.
[20]WANG P,DOXTADER KA,NAM Y.Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases[J].Mol Cell,2016,63(2):306-317.
[21]MA L,HUA RX,LIN H,et al.The contribution of WTAP gene variants to Wilms tumor susceptibility[J].Gene,2020,754:144839.
[22]PING XL,SUN BF,WANG L,et al.Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase[J].Cell Res,2014,24(2):177-189.
[23]LAN T,LI H,ZHANG D,et al.KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3[J].Mol Cancer,2019,18(1):186.
[24]WANG T,KONG S,TAO M,et al.The potential role of RNA N6-methyladenosine in cancer progression[J].Mol Cancer,2020,19(1):88.
[25]KNUCKLES P,LENCE T,HAUSSMANN IU,et al.Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m(6)A machinery component Wtap/Fl(2)d[J].Genes Dev,2018,32(5-6):415-429.
[26]WEN J,LYU R,MA H,et al.Zc3h13 regulates nuclear RNA m(6)A methylation and mouse embryonic stem cell self-renewal[J].Mol Cell,2018,69(6):1028-1038.
[27]ZHAO W,QI X,LIU L,et al.Epigenetic regulation of m(6)A modifications in human cancer[J].Mol Ther Nucleic Acids,2020,19:405-412.
[28]YUE Y,LIU J,CUI X,et al.VIRMA mediates preferential m(6)A mRNA methylation in 3' UTR and near stop codon and associates with alternative polyadenylation[J].Cell Discov,2018,4:10.
[29]LI J,HAN Y,ZHANG H,et al.The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA[J].Biochem Biophys Res Commun,2019,512(3):479-485.
[30]NIU Y,ZHAO X,WU YS,et al.N6-methyl-adenosine (m6A) in RNA:an old modification with a novel epigenetic function[J].Genomics Proteomics Bioinformatics,2013,11(1):8-17.
[31]WANG J,WANG J,GU Q,et al.The biological function of m6A demethylase ALKBH5 and its role in human disease[J].Cancer Cell Int,2020,20:347.
[32]YU H,YANG X,TANG J,et al.ALKBH5 inhibited cell proliferation and sensitized bladder cancer cells to cisplatin by m6A-CK2α-mediated glycolysis[J].Mol Ther Nucleic Acids,2021,23:27-41.
[33]REICHEL M,KSTER T,STAIGER D.Marking RNA:m6A writers,readers,and functions in Arabidopsis[J].J Mol Cell Biol,2019,11(10):899-910.
[34]PATIL DP,CHEN CK,PICKERING BF,et al.m(6)A RNA methylation promotes XIST-mediated transcriptional repression[J].Nature,2016,537(7620):369-373.
[35]ANITA R,PARAMASIVAM A,PRIYADHARSINI JV,et al.The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients[J].Am J Cancer Res,2020,10(8):2546-2554.
[36]HE L,LI H,WU A,et al.Functions of N6-methyladenosine and its role in cancer[J].Mol Cancer,2019,18(1):176.
[37]MEYER KD,JAFFREY SR.Rethinking m(6)A readers,writers,and erasers[J].Annu Rev Cell Dev Biol,2017,33:319-342.
[38]SHI H,WEI J,HE C.Where,when,and how:Context-dependent functions of RNA methylation writers,readers,and erasers[J].Mol Cell,2019,74(4):640-650.
[39]CHANG G,SHI L,YE Y,et al.YTHDF3 induces the translation of m(6)A-enriched gene transcripts to promote breast cancer brain metastasis[J].Cancer Cell,2020,38(6):857-871.
[40]LIU N,DAI Q,ZHENG G,et al.N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions[J].Nature,2015,518(7540):560-564.
[41]ALARCON CR,GOODARZI H,LEE H,et al.HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events[J].Cell,2015,162(6):1299-1308.
[42]HUANG H,WENG H,SUN W,et al.Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation[J].Nat Cell Biol,2018,20(3):285-295.
[43]SHI H,WANG X,LU Z,et al.YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA[J].Cell Res,2017,27(3):315-328.
[44]CATE JH.Human eIF3:from 'blobology' to biological insight[J].Philos Trans R Soc Lond B Biol Sci,2017,372(1716):20160176.
[45]LIU S,LI G,LI Q,et al.The roles and mechanisms of YTH domain-containing proteins in cancer development and progression[J].Am J Cancer Res,2020,10(4):1068-1084.
[46]LIU T,WEI Q,JIN J,et al.The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation[J].Nucleic Acids Res,2020,48(7):3816-3831.
[47]OROUJI E,PEITSCH WK,OROUJI A,et al.Oncogenic role of an epigenetic reader of m(6)A RNA modification:YTHDF1 in merkel cell carcinoma[J].Cancers(Basel),2020,12(1):202.
[48]YARMISHYN AA,YANG YP,LU KH,et al.Musashi-1 promotes cancer stem cell properties of glioblastoma cells via upregulation of YTHDF1[J].Cancer Cell Int,2020,20(1):597.
[49]PAN S,WU W,REN F,et al.MiR-346-5p promotes colorectal cancer cell proliferation in vitro and in vivo by targeting FBXL2 and activating the β-catenin signaling pathway[J].Life Sci,2020,244:117300.
[50]LI Y,XU J,ZHANG J,et al.MicroRNA-346 inhibits the growth of glioma by directly targeting NFIB[J].Cancer Cell Int,2019,19:294.
[51]XU C,YUAN B,HE T,et al.Prognostic values of YTHDF1 regulated negatively by miR-3436 in glioma[J].J Cell Mol Med,2020,24(13):7538-7549.
[52]杨蕊,朱奕,王颖,等.丙酮酸脱氢酶激酶PDK4在临床中的研究进展[J].中国医院药学杂志,2019,39(01):101-105.
YANG R,ZHU Y,WANG Y,et al.Research progress of pyruvate dehydrogenase kinase PDK4 in clinic[J].Chin J Hosp Pharm,2019,39(01):101-105.
[53]LI Z,PENG Y,LI J,et al.N(6)-methyladenosine regulates glycolysis of cancer cells through PDK4[J].Nat Commun,2020,11(1):2578.
[54]DIXIT D,AHMAD F,GHILDIYAL R,et al.CK2 inhibition induced PDK4-AMPK axis regulates metabolic adaptation and survival responses in glioma[J].Exp Cell Res,2016,344(1):132-142.
[55]HOSONO Y,NIKNAFS YS,PRENSNER JR,et al.Oncogenic role of THOR,a conserved cancer/testis long non-coding RNA[J].Cell,2017,171(7):1559-1572.
[56]XUE J,ZHONG S,SUN BM,et al.Lnc-THOR silencing inhibits human glioma cell survival by activating MAGEA6-AMPK signaling[J].Cell Death Dis,2019,10(11):866.
[57]LIU H,XU Y,YAO B,et al.A novel N6-methyladenosine (m6A)-dependent fate decision for the lncRNA THOR[J].Cell Death Dis,2020,11(8):613.
[58]PI J,WANG W,JI M,et al.YTHDF1 promotes gastric carcinogenesis by controlling translation of FZD7[J].Cancer Res,2021,81(10):2651-2665.
[59]QIU X,JIAO J,LI Y,et al.Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ[J].Oncotarget,2016,7(52):85987-85999.
[60]LIU Q,GUAN Y,LI Z,et al.miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway[J].J Exp Clin Cancer Res,2019,38(1):358.
[61]刘德仁,丁闯,侍孝红,等.c-Myc在人胃癌组织中的表达及其对胃癌细胞增殖、迁移和侵袭的影响[J].现代肿瘤医学,2021,29(20):3526-3531.
LIU DR,DING C,SHI XH,et al.Expression of c-Myc in human gastric cancer tissues and its effect on proliferation,migration and invasion of gastric cancer cells[J].Modern Oncology,2021,29(20):3526-3531.
[62]WANG J,WANG H,LI Z,et al.c-Myc is required for maintenance of glioma cancer stem cells[J].PLoS One,2008,3(11):e3769.
[63]NISHIZAWA Y,KONNO M,ASAI A,et al.Oncogene c-Myc promotes epitranscriptome m(6)A reader YTHDF1 expression in colorectal cancer[J].Oncotarget,2018,9(7):7476-7486.
[64]LIU X,QIN J,GAO T,et al.YTHDF1 facilitates the progression of hepatocellular carcinoma by promoting FZD5 mRNA translation in an m6A-dependent manner[J].Mol Ther Nucleic Acids,2020,22:750-765.
[65]TANG R,ZHANG Y,LIANG C,et al.The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma[J].PeerJ,2020,8:e9602.
[66]HAN D,LIU J,CHEN C,et al.Author correction:Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells[J].Nature,2019,568(7751):E3.
[67]CHEN PY,WU CY,FANG JH,et al.Functional change of effector tumor-infiltrating CCR5(+)CD38(+)HLA-DR(+)CD8(+) T cells in glioma microenvironment[J].Front Immunol,2019,10:2395.
[68]SHI Y,FAN S,WU M,et al.YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression[J].Nat Commun,2019,10(1):4892.
[69]LIU X,CHEN J,LI W,et al.Inhibition of casein kinase II by CX-4945,but not Yes-associated protein(YAP) by verteporfin,enhances the antitumor efficacy of temozolomide in glioblastoma[J].Transl Oncol,2020,13(1):70-78.
[70]LIU T,XU H,HUANG M,et al.Circulating glioma cells exhibit stem cell-like properties[J].Cancer Res,2018,78(23):6632-6642.